Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Medical System Holdings ( (HK:0867) ) has issued an update.
China Medical System Holdings Limited has entered into a Distribution Agreement with Novartis Pharma Services AG for the exclusive rights to distribute Lucentis® and Beovu® in mainland China. This agreement enhances the company’s portfolio in the ophthalmic drug market, allowing it to capitalize on the growing demand for anti-VEGF drugs in China, projected to expand significantly by 2030. The inclusion of Lucentis®, a well-established treatment for ocular neovascular diseases, and Beovu®, a novel treatment for diabetic macular edema, strengthens the company’s position in the ophthalmic sector and offers potential growth opportunities.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings Limited is a company involved in the pharmaceutical industry, focusing on the distribution and promotion of medical products. The company primarily deals with ophthalmic drugs and has a significant market focus in China.
YTD Price Performance: 78.50%
Average Trading Volume: 8,823,487
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.96B
Find detailed analytics on 0867 stock on TipRanks’ Stock Analysis page.